DATE – May 30, 2018

The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with ACME Resources Corp.'s ("ACME" or the "Company" or the "Corporation") interim (unaudited) financial statements and the accompanying notes for the six-month period ended March 31, 2018, copies of which are filed on SEDAR website: www.sedar.com.

The Company prepares its financial statements in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board. All dollar figures included herein and in the following discussion and analysis are quoted in Canadian dollars unless otherwise stated.

The financial information in this MD&A is derived from the Company's financial statements prepared in accordance with IFRS. This MD&A may contain forward looking statements based on assumptions and judgements of management regarding events or results that may prove to be inaccurate as a result of risk factors beyond its control. Actual results may differ materially from the expected results.

FORWARD LOOKING STATEMENTS

This MD&A may include certain "forward-looking statements" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical facts, included in this MD&A that address activities, events or developments that the Corporation expects or anticipates will or may occur in the future, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company's businesses, operations, plans and other such matters are forward-looking statements. When used in this MD&A, the words "estimate", "plan", "anticipate", "expect", "intend", "believe" and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

DESCRIPTION OF THE BUSINESS AND PROPOSED QUALIFYING TRANSACTION

ACME was incorporated under the *Business Corporations Act* (Ontario) on February 27, 2008 and is classified as a Capital Pool Company ("CPC") as defined in Policy 2.4 of the TSX Venture Exchange (the "TSXV" or "Exchange").

On January 28, 2010, the Company received final receipts for a prospectus and thereafter began trading on the TSXV (Tier 2) as a CPC under the symbol ACY.P; however, as the Company did not complete a Qualifying Transaction within the necessary timeframe, the Company's listing was transferred to the NEX board of Exchange ("NEX") in 2012 and henceforth traded under the symbol ACY.H. As a CPC listed on NEX, the Company continued to be required to comply with all of the requirements and restrictions in Exchange Policy 2.4.

On October 21, 2013, the Company entered into an amalgamation agreement (the "Agreement") with Forrester Resources Corp., a private Yukon precious metals exploration and development corporation ("Forrester") operating in Perú and continually investigating near-term production opportunities within the Americas. Under the terms of the Agreement, Forrester was to amalgamate (the "Transaction" or "Qualifying Transaction") with a new wholly owned subsidiary of the Company incorporated in the Yukon. Pursuant to the terms of the Transaction, the Company's shares were to be issued to holders of Forrester shares in exchange for all of the issued and outstanding Forrester shares on the basis of 1.5 of the Company's shares for each one Forrester share. In addition, Forrester options, warrants and finder's warrants were to be exchanged for the Company's options, warrants and finder's warrants on the same foregoing exchange ratio, with a corresponding adjustment of the exercise price of each such Forrester option and warrant to reflect the exchange ratio.

On June 25, 2014, the Company terminated the proposed Qualifying Transaction with Forrester. Forrester Resources Corp. had advanced \$41,417 to fund corporate costs relevant to the proposed Qualifying Transaction and the ongoing costs related to running a public company; the advances were written-off as failed transaction costs by Forrester and they consider the amounts as settled in full.

As a consequence of the abandonment of the proposed Transaction, the Company's shares were halted from trading. The Company anticipated they would remain halted until certain documentation could be provided to the TSXV regarding the termination and the Company continued to identify and evaluate businesses and assets with a view of completing a qualifying transaction.

The Company completed a non-brokered private placement financing which closed on December 11, 2014 at which time the Company issued a total of 1,300,000 Common Shares for gross proceeds of \$65,000. On December 15, 2014 shares of the Company resumed trading on the NEX.

The Company completed a non-brokered private placement which closed on November 11, 2015 at which time the Company issued a total of 700,000 Common Shares for gross proceeds of \$35,000.

The Company announced that it entered into a letter of intent dated December 7, 2015 with Hantian Labs Limited ("Hantian"), a private UK corporation, for a business transaction that would result in a reverse take-over of the Company by Hantian, and the listing or trade of the shares of the resulting issuer on the TSXV (the "LOI"). Trading of the shares of the Company on the NEX was halted pending the completion of the business transaction.

The transaction was subject to TSXV approval and was intended to constitute the Qualifying Transaction of the Company as such term is defined in Policy 2.4 of the TSXV. It was intended that the Transaction would be completed by way of a definitive merger, amalgamation or share exchange agreement, provided however that, by mutual agreement, the parties may revise the structure to comply with all necessary legal and regulatory requirements, to minimize or eliminate any adverse tax consequences or to increase cost effectiveness. The Transaction was intended to result in a reverse take-over of the Company by Hantian's shareholders. The Transaction would be an Arm's Length Qualifying Transaction, as defined in the policies of the TSXV and, as such, it was not anticipated that the formal approval of the shareholders of the Company would be required.

The Company and Hantian agreed to use all commercially reasonable efforts to close the Transaction by September 30, 2016. The LOI would terminate in the event the parties failed to enter into a definitive agreement on or prior to January 31, 2016, unless a later date was otherwise mutually agreed to by the

parties. Pursuant to the Transaction, shares of the Company would be issued to the holders of Hantian shares in exchange for all of the issued and outstanding Hantian shares on the basis of one ACME share for each Hantian share.

On January 29, 2016 the Company announced that it had amended its original LOI (the "**First Amendment**"). The Company and Hantian agreed to extend the settlement of a Definitive Agreement until September 30, 2016 and the closing of the Transaction until May 31, 2016. The LOI was to terminate in the event the parties failed to enter into a Definitive Agreement on or prior to January 31, 2016, unless a later date was otherwise mutually agreed to by the parties.

On March 29, 2016, the Company and Hantian agreed to extend the settlement of a Definitive Agreement until July 31, 2016 and the closing of the Transaction until October 31, 2016 (the "Second Amendment"). As per the First Amendment, the LOI was to terminate in the event the parties failed to enter into a Definitive Agreement on or prior to September 30, 2016, unless a later date was otherwise mutually agreed to by the parties.

On August 18, 2016, the Company announced that its intention to complete a business transaction with Hantian as originally considered in the LOI dated December 7, 2015, had terminated. ACME and Hantian had agreed to the settlement of a Definitive Agreement by July 31, 2016; acceptable terms and conditions relating to a Definitive Agreement could not be negotiated by the parties in that time frame and the LOI was allowed to expire by the parties. The termination fee of \$50,000 was waived by both parties.

The Company held an Annual and Special Meeting on the 24th of October, 2017 (the "**Special Meeting**"). At the Special Meeting the Company received a requisite majority of its shareholders approval to proceed with a voluntary delisting from the TSXV for the purpose of seeking a listing on an alternative stock exchange.

Also at the Special Meeting, the Company received the requisite majority of its shareholders approval to proceed with the consolidation of its common shares on a 1:5 (new:old) basis (the "Consolidation"). Concurrent with the Consolidation, the Company would also cancel 209,142 (41,828 post-consolidation) options and 750,000 (150,000 post-consolidation) escrowed founders' shares. The cancellation of the escrowed founders' shares is pursuant to Policy 2.4 of the TSXV, as the Company was originally listed as a CPC on the TSXV. The record date for the consolidation became February 5, 2018. A name change for the consolidated Company is pending; the authority for management to change the name of the Company was approved by a majority of its shareholders at the Special Meeting.

Upon the Consolidation becoming effective on February 16, 2018, the 10,080,950 issued and outstanding common shares as at the date thereof would be consolidated into 2,016,190 issued and outstanding common shares. In connection with the Consolidation, the Company sent letters of transmittal to holders of common shares for use in transmitting their share certificates to the Depository, Capital Transfer Agency ULC, in exchange for new certificates representing the number of post-consolidated common shares to which such shareholder is entitled as a result of the Consolidation. No delivery of a new share certificate to a shareholder will be made until the shareholder has surrendered his, her or its current issued share certificates. Until surrendered, each share certificate formerly representing old common shares will be deemed for all purposes to represent the number of post-consolidated common shares to which such holder is entitled as a result of the Consolidation.

No fractional shares will be issued in connection with the Consolidation; if, as a result of the Consolidation, a shareholder becomes entitled to a fractional share, such fraction will be rounded down to

the nearest whole number. The Consolidation will not give rise to a capital gain or a capital loss under the *Income Tax Act* (Canada) for a shareholder who holds common shares as capital property. The aggregate adjusted cost base to the shareholder of his, her or its new common shares immediately after the Consolidation will be equal to the aggregate adjusted cost base of his, her or its common shares immediately before the Consolidation.

In connection with the Special Meeting held on the 24th of October, 2017, the Company's Management Information Circular ("**MIC**") provided additional details of these matters and other items put forward at the Annual and Special Meeting and the MIC is available under the Company's filings on SEDAR. The Company noted a correction to page 13 of the MIC wherein it was incorrectly reported that the number of common shares held by promoters, directors, officers and other insiders of the Company ineligible to vote on the "Delisting Resolutions" (as that term is defined in the MIC) was 4,991,950, whereas the correct number is 1,350,000.

The Company continued to explore business opportunities. On February 6, 2018 the Company announced that it had signed a letter of intent ("**LOI**") with Rapid Dose Therapuetics Inc. ("**RDT**") for a transaction which would constitute a proposed Reverse Take-Over of the Company. The intent is for the parties to enter into a definitive binding agreement (the "**Definitive Agreement**") for the acquisition by ACME of 100% of the issued share capital of RDT in a Reverse Take-Over transaction (the "**Transaction**"), payable by the issuance of up to 57,130,000 common shares of ACME, which shares include a private placement by RDT (the "RDT-PP) prior to closing for gross proceeds of up to \$2,000,000.

The parties have agreed to a finders' fee on closing to an arm's length party equal to 7% of the total number of shares as at the closing date.

RDT is a private Canadian bio-technology company which provides proprietary enhanced drug delivery technologies designed to improve patient outcomes. RDT owns a proprietary oral fast-dissolving drug delivery system, QuickStripTM, which is capable of rapidly releasing into the blood stream a list of pharmaceuticals, emulsified oils and over-the-counter medicines without being degraded or modified by first pass metabolism in the liver. RDT also provides product innovation, production and consultation to the pharmaceutical and healthcare manufacturing industry.

Closing of the Definitive Agreement will be subject to approval of regulatory authorities and compliance with any required governmental and securities regulations. Closing will also be conditional on approval for listing of the ACME shares on an alternate stock exchange in Canada. ACME intends to change its name to RAPID DOSE THERAPEUTICS CORP., or another name as appropriate. *There is no guarantee that the Definitive Agreement will close*.

The Company completed a shares-for-debt transaction (the "**Debt Transaction**") whereby ACME issued 1,400,000 post-consolidation (7,000,000 pre-consolidation) common shares (of which 575,000 shares were issued to insiders of the Company) at a deemed price of \$0.125 per common share (\$0.025 or $2\frac{1}{2}$ ¢ per pre-consolidated share) in connection with the repayment of \$175,000 in debt. The Debt Transaction was undertaken by ACME in order to conserve capital and improve the Company's balance sheet. The common shares issued in connection with the Debt Transaction are be subject to a statutory four month plus one day hold period.

The TSXV/NEX suspended the Company from trading on February 22, 2018. In late March, the Company was advised by the TSXV that due to the Company's breach of Exchange policies and its Listings Agreement, the TSXV initiated an involuntary delist review and proceeded to delist the shares of

the Company for failure to comply with Exchange Requirements to wit:

- 1) Pursuant to Policy 5.8 Issuer Names, Issuer Name Changes, Share Consolidations and Splits, the Company failed to file and obtain TSXV approval prior to effecting the 5 old for 1 new share consolidation.
- 2) Prior to the completion of the Consolidation, the Company completed non-brokered private placement offerings of Company equity pursuant to Policy 4.4 Private Placements without obtaining conditional or final acceptance. The private placements comprised an offering of 5,579,000 common shares at a price of \$0.025 (2½¢) per common share for gross proceeds of \$139,475. The proposed price of \$0.025 was less than the minimum price permitted under Exchange Policy and was previously disallowed.
- 3) The Company completed a shares-for-debt transaction pursuant to Policy 4.3 Shares for Debt whereby the Company issued 7,000,000 common per common share at \$0.025 per common share in connection with the settlement of \$175,000 debt. The price per share was less than the minimum price permitted under Exchange Policy. The nature of the accrued debt contravenes the "Prohibited Payments and Use of Proceed" under Policy 2.4.
- 4) Subsequent to the completion of the Consolidation, the Company has also cancelled the remaining 150,000 escrowed founders' shares (750,000 on a pre-consolidation basis). The cancellation of the escrowed founders' shares was undertaken pursuant to Policy 2.4 of the TSXV. The first half of the original total of 300,000 (1,500,000 on a pre-consolidation basis) escrowed founders' shares had already been cancelled in fiscal year 2012 due to the Company failing to complete a Qualifying Transaction within the time allotted per Policy 2.4. At this time the Company was also transferred to the NEX Tier of the TSXV.
- 5) At the Shareholders Meeting, Mr. Brian Howlett was elected as a new Director of the Company. His election has previously been noted in publicly filed documents but had not been disclosed in a press release issued by the Company. The Company failed to comply with Policy 2.4 in connection with the change in the board.

The Company was delisted from the TSXV at the end of business on March 28, 2018.

On March 29, 2018 the Company announced that it had closed a non-brokered private-placement offering of 2,006,000 common shares issued at a price of \$0.25 per share (the "**Offering**") for gross proceeds of \$501,500. All securities issued in connection with the Offering are subject to a statutory four month plus one day hold period.

The proceeds received from the Offering were for general working capital purposes while the Company continued its restructuring and works toward completing a Definitive Agreement with RDT as previously reported.

RESULTS OF OPERATIONS AND OVERALL PERFORMANCE

For the six-month period ended March 31, 2018, the Company reported a net loss of \$251,654 compared to a loss of \$17,105 during the six-month period ended March 31, 2017. The operating expenses comprised of corporate development of \$9,749 (2017 - \$4,993), consulting fees of \$152,548 (2017 - \$nil),

professional fees of \$21,250 (2017 - \$4,212), regulatory and filing fees of \$27,815 (2017 - \$4,228), office, general and administration fees of \$40,001 (2017 - \$3,500) and bank charges of \$291 (2017 - \$172).

The foregoing costs incurred by the Company primarily relate to fees incurred in connection with the operation of a reporting issuer. Consulting fees were higher for the period as a result of management's effort to restructure the Company and complete a business transaction with RDT.

Since incorporation, the Company has been actively engaged in the identification of target companies for the purposes of completing a qualifying transaction, including the aforementioned negotiations with Forrester, Hantian and RDT.

During the period ended September 30, 2008, the Company issued 1,500,000 common shares at a price of \$0.10 per share for total proceeds of \$150,000 received in cash. In accordance with the requirements of the Exchange these common shares are held in escrow. Under the escrow agreement, 10% of the escrowed common shares will be released from escrow following issuance of the Final Exchange Bulletin by the Exchange as to completion of the Qualifying Transaction as defined by Exchange policies, and 15% will be released every six months following the initial release over a period of thirty-six months, unless otherwise permitted by the Exchange.

On October 30, 2009, the Company filed its final prospectus for which a receipt was issued dated October 30, 2009.

On January 28, 2010, the Company completed its initial public offering ("**PO**") through its agent Integral Wealth Securities Limited of 1,351,950 common shares for gross proceeds of \$270,390. The Company paid the agent a cash commission of \$27,039 and a corporate finance fee of \$10,000, reimbursed the agent for legal fees and other direct expenses of \$10,150, and issued Agent's options to acquire up to 135,195 common shares at \$0.20 per share exercisable until the close of business on the second anniversary of the Company's listing on the Exchange (January 28, 2010). The Company also incurred, in connection with the IPO, professional fees and filing fees of \$93,200.

The Company granted stock options to directors and officers of the Company to purchase up to 285,194 common shares at a price of \$0.20 per share, exercisable for ten years from the date of grant.

On December 28, 2016, the company issued 1,899,000 common shares for gross proceeds of \$47,475.

The TSXV commenced a review on the Company's compliance with certain requirements and restrictions in conjunction with Policy 2.4 of the TSX Venture Exchange.

The Company arranged a non-brokered private-placement offering of Company equity. This private placement was to comprise an offering of up to 7,000,000 common shares at a price of 0.025 (0.025) per share for gross proceeds of up to 0.025 (0.025) per share for gross proceeds of up to 0.025 (0.025) was distributed in November 2017. All securities issued in connection with the financing were subject to a statutory four month plus one day hold period from the date of issuance. It was deemed critical by management to execute this private placement at a price per share less than the TSXV would normally allow due to extenuating circumstances: the Company had no further funds and its officers and directors could no longer personally pay for the expenses necessary to maintain the Company's status as a reporting issuer, including such payments as the preparation and filing of quarterly financial statements and year-end audited financial statements, as well as paying TSXV and transfer agent fees.

The proceeds received from the private-placement offering were used for general working capital purposes while the Company continued to explore options business opportunities and the acquisition of a significant asset for the Company (this acquisition could be considered to be a Qualifying Transaction as such term is defined in Policy 2.4).

The Company held an Annual and Special Meeting on the 24th of October, 2017. At that Meeting the Company received a majority of shareholder support to approve: 1) the election of Directors; 2) the Stock Option Plan; 3) the voluntary delisting from the TSXV for the purpose of seeking a listing on an alternative stock exchange; 4) the consolidation of the common shares of the Company on an up to 1:5 (new:old) basis; and 5) the authority for management to change the name of the consolidated Company.

A total of 38,026 options, originally granted to a former director, terminated in November 2017. The remaining options outstanding at that time (209,142) were all subsequently cancelled by the Company.

As of the end of the six-month period ended March 31, 2018, the Company has outstanding common shares of 5,272,190 and nil stock options and warrants.

SELECT ANNUAL INFORMATION

The following financial data, which has been prepared in accordance with IFRS, is derived from the Company's audited financial information for the year ended September 30, 2017 and 2016:

Financial Results	2017	2016
Total revenues	Nil	Nil
Net loss for the year	(\$50,079)	(\$ 47,097)
Basic and diluted net loss per share	(\$ 0.01)	(\$ 0.01)
Total assets	\$17,064	\$903
Total long-term liabilities	Nil	Nil

The preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from these estimates.

SUMMARY OF QUARTERLY REPORTS

The Company's operating results for the previous two years (previous seven quarters and the six-month period ended March 31, 2018) are summarized as follows:

	Dec. 31, 2017		March 31, 2018		
		Q1		Q2	
Revenue		-		-	
Net loss	(\$	19,044)	(\$	232,210)	
Basic and diluted loss per share	(\$	0.003)	(\$	0.07)	

	Dec. 31, 2016 Q1		March 31, 2017 Q2		June 30, 2017 Q3		Sept. 30, 2017 Q4	
Revenue		-		-		-		-
Net loss	(\$	13,090)	(\$	4,015)	(\$	6,442)	(\$	26,532)
Basic and diluted loss per share	(\$	0.003)	(\$	0.001)	(\$	0.001)	(\$	0.001)
					June 30, 2016 Q3		Sept. 30, 2016 Q4	
Revenue						-		-
Net loss					(\$	1,904)	(\$	16,076)
Basic and diluted loss per share					(\$	0.001)	(\$	0.004)

LIQUIDITY

The Company does not currently have any interest in property and does not generate revenues from operations. The Company has been financed to date through equity financing and it expects that it will be able to do so in the future until it generates cash flows from operations.

As of March 31, 2018, the Company had net working capital surplus of \$470,203 (March 31, 2017 – working capital deficiency of \$9,801) and a cash balance of \$345,368 (March 31, 2017 – \$5,768). The Company's cash position is sufficient to meet short term obligations. The Company may require additional funds to complete its currently anticipated business transaction. The Company currently relies on private placements for funding.

As of the date hereof, the Company did not have any commitments for capital expenditures, and the Company does not anticipate any such commitments until it consummates its business transaction.

CAPITAL MANAGEMENT

Capital is comprised of the Company's shareholders' equity and any debt that it may issue. As at March 31, 2018, the Company's shareholders' equity was a surplus of \$470,203 (March 31, 2017 – deficiency of \$9,801) and it had no outstanding long-term debt. The Company's objectives when managing capital are to maintain financial strength and to protect its ability to meet its on-going liabilities, to continue as a going concern, to maintain creditworthiness and to maximize returns for shareholders over the long term.

The Company's sole source of capital has been from the issuance of common shares. The net proceeds raised may only be used (with the exception of certain permitted uses of funds by a capital pool company to cover prescribed costs of issuing shares and administrative and general expense – see below) to identify and evaluate a limited number of assets and businesses for the purpose of identifying and completing a Qualifying Transaction. Additional funds may be required to finance the Company's Qualifying Transaction.

The proceeds raised from the issuance of share capital may only be used to identify and evaluate assets of businesses for future investment, with the exception that the lesser of 30% of the gross proceeds and \$210,000 may be used to cover prescribed costs of issuing the common shares, other than Agent Commissions and fees, and general and administrative expense of the Company. These restrictions apply

until completion of a Qualifying Transaction by the Company as defined under the policies of the Exchange.

As at March 31, 2018, the Company has exceeded the limit. There are potential ramifications associated with exceeding this limit without relief which will be assessed at the discretion of the Exchange.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance sheet arrangements as at March 31, 2018 or as of the date of this report.

TRANSACTIONS WITH RELATED PARTIES

The Company's key management personnel have the authority and responsibility for planning, directing and controlling the activities of the Company and consists of its Directors, Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"). Total compensation paid to the Company's key management personnel during the six-month period ended March 31, 2018 was \$46,875 (2017 - \$nil) for the CEO and \$15,625 (2017 - \$nil) for the CFO. No share based-payments, post-employment or other long-term benefits were incurred with respect to key management personnel in respect of the forgoing periods.

FINANCIAL INSTRUMENTS

Financial instruments include cash and accounts payable and accrued liabilities. The estimated fair value of these financial instruments approximates their carrying values because of the short term to maturity of these instruments. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from financial instruments. In regards to liquidity risk, the Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due.

The Company currently has current liabilities of \$17,315 (September 30, 2017 - \$29,839) and current assets of \$487,518 (September 30, 2017 - \$17,064). The Company has a working capital surplus of \$470,203 (September 30, 2017 – working capital deficiency of \$12,775). The ability of the Company to survive is dependent on its ability to secure additional equity or other financings.

CRITICAL ACCOUNTING ESTIMATES

The financial statements have been prepared in accordance with accounting principles generally accepted in Canada and form the basis for the following discussion and analysis of critical accounting policies and estimates. The Company makes estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and related disclosure of contingent assets and liabilities during the course of preparing these financial statements.

Management has made a number of significant estimates and valuation assumptions, including the stock option valuations, going concern assumption, deferred income tax recognition and disclosures of contingent assets and liabilities at the date of the financial statements. These estimates and assumptions are based on present conditions and management's planned course of action as well as assumptions about future business and economic conditions. Should the underlying estimates change, the recorded amounts could change by a material amount.

For a detailed summary of the Company's significant accounting policies, the reader is directed to Note 3 of the Notes to the audited Financial Statements for the six-month period ended March 31, 2018 available on SEDAR at www.sedar.com.

ACCOUNTING AND REPORTING CHANGES

Effective for annual periods beginning on or after January 1, 2018

IFRS 9, Financial Instruments – Classification and Measurement, is a new standard on financial instruments that will replace IAS 39, Financial Instruments: Recognition and Measurement. IFRS 9 addresses classification and measurement of financial assets and financial liabilities as well as derecognition of financial instruments. IFRS 9 has two measurement categories for financial assets: amortized cost and fair value. All equity instruments are measured at fair value. A debt instrument is at amortized cost only if the entity is holding it to collect contractual cash flows and the cash flows represent principal and interest. Otherwise it is at fair value through profit or loss.

The Company has not early adopted these revised standards and none of these standards are expected to have a material effect on the financial statements.

RISKS AND UNCERTAINTIES

The Corporation has no active business or assets other than cash, accounts receivable and deferred transaction costs. The Corporation does not have a history of earnings, nor has it paid any dividends and will not generate earnings or pay dividends until at least after the Completion of the Qualifying Transaction. The Corporation has only limited funds with which to identify and evaluate possible Qualifying Transactions and there can be no assurance that the Corporation will be able to identify or complete a suitable Qualifying Transaction.

The Company competes with many Capital Pool Companies that are seeking suitable Qualifying Transactions. In addition, other Capital Pool Companies may have substantially greater financial and technical resources than the Company.

Any forward-looking information in this MD&A is based on the conclusions of management. The Company cautions that due to risks and uncertainties, actual events may differ materially from current expectations. With respect to the Company's operations, actual events may differ from current expectations due to economic conditions, new opportunities, changing budget priorities of the company and other factors.

OTHER MATTERS

Legal proceedings

There are no ongoing legal proceedings of any kind initiated by the Company or by third parties against the Company.

Contingent liabilities

At the date of MD&A, management was unaware of any outstanding contingent liability relating to the Company's activities.

Disclosure Controls and Procedures

The Chief Executive Officer and Chief Financial Officer ("CFO") are responsible for designing internal controls over financial reporting in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company's financial statements for external purposes in accordance with IFRS. The design of the Company's internal control over financial reporting was assessed as of the date of this Management Discussion and Analysis.

Based on this assessment, it was determined that certain weaknesses existed in internal controls over financial reporting. As indicative of many small companies, the lack of segregation of duties and effective risk assessment were identified as areas where weaknesses existed. The existence of these weaknesses is to be compensated for by senior management monitoring, which exists. The officers will continue to monitor very closely all financial activities of the Company and increase the level of supervision in key areas. It is important to note that this issue would also require the Company to hire additional staff in order to provide greater segregation of duties. Since the increased costs of such hiring could threaten the Company's financial viability, management has chosen to disclose the potential risk in its filings and proceed with increased staffing only when the budgets and work load will enable the action.

The Company has attempted to mitigate these weaknesses, through a combination of extensive and detailed review by the CFO of the financial reports, the integrity and reputation of accounting personnel, and candid discussion of those risks with the audit committee.

Business Risks

The Company has a limited history of operations and has not yet entered into an agreement in principle to acquire or complete a qualifying transaction. The Company is currently in the process of identifying and evaluating opportunities and until such a time as it enters into an agreement to complete a qualifying transaction, there is no guarantee such a transaction will be completed. External financing, primarily through the issuance of common shares will be required to fund the Company's activities. There can be no assurance that the Company will be able to obtain adequate financing. The Securities of the Company should be considered a highly speculative investment. The following risk factors should be given special consideration when evaluating an investment in any of the Company's Securities:

<u>Dilution:</u> There are a number of outstanding securities and agreements pursuant to which common shares of the Company may be issued in the future. This will result in further dilution to the Company's shareholders.

Revenues and Dividends: The Company has no revenues and does not expect to have any revenues in the foreseeable future. In the event that the Company generates any meaningful revenues in the future, then the Company intends to retain its earnings in order to finance further growth. Furthermore, the Company has not paid any dividends in the past and does not expect to pay any dividends in the future.

OUTLOOK

The Company's primary focus for the foreseeable future will be completing its identified business transaction.

APPROVAL

The Board of Directors of the Company has approved the disclosures contained in this MD&A upon recommendation of the Audit Committee.

EVENTS AFTER THE REPORTING DATE AND COMMITMENTS

On April 9, 2018 the Company announced that it had entered into a definitive agreement to acquire 100% of the issued share capital of Rapid Dose Therapeutics Inc. ("**RDT**") in a Reverse Take-Over transaction payable by the issuance of up to 57,130,000 common shares of ACME, which shares will include a private placement by RDT, prior to closing, for gross proceeds of up to \$2,000,000.

Closing of the Definitive Agreement will be subject to approval by regulatory authorities and compliance with any required governmental and securities regulations. Closing will also be conditional on approval for listing of the ACME shares on the Canadian Securities Exchange. ACME intends to change its name to RAPID DOSE THERAPEUTICS CORP., or another name as appropriate. There is no guarantee that the Definitive Agreement will close.

The parties have agreed to pay a finder's fee on closing to an arm's length party equal to 7% of the total number of shares issued and outstanding as at closing.

Upon closing of the Definitive Agreement, the Company will have up to 66,763,923 issued and outstanding common shares of which approximately 8% will comprise the existing ACME shareholders, and approximately 85% will comprise the former RDT shareholders.

The Company incorporated a wholly owned subsidiary, 1163926 B.C. LTD., under the *British Columbia Business Corporations Act* on May 11, 2018.

DIRECTORS AND OFFICERS

Paul R. Ankcorn, *President, Chief Executive Officer and Director*Brian M. Cloney, *Chief Financial Officer, Corporate Secretary and Director*Brian Howlett, *Director*Harry Burgess, *Director*Kees C. Van Winters, *Director*

DISCLOSURE OF OUTSTANDING SECURITIES AS AT MAY 30, 2018

Outstanding common shares: 5,272,190
Share purchase and finders warrants: nil
Stock options: nil

Fully diluted: 5,272,190

MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

In connection with Exemption Orders issued in November 2007 by each of the securities commissions across Canada, the Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") of the Company will file a Venture Issuer Basic Certificate with respect to the financial information contained in the unaudited interim financial statements and the audited annual financial statements and respective accompanying Management's Discussion and Analysis.

In contrast to the certificate under Multilateral Instrument ("MI") 52-109 (Certification of Disclosure in Issuer's Annual and Interim Filings), the Venture Issuer Basic Certification includes a 'Note to Reader' stating that the CEO and CFO do not make any representations relating to the establishment and maintenance of disclosure controls and procedures and internal control over financial reporting, as defined in MI 52-109.

OTHER REQUIREMENTS

Additional disclosure of the Company's material change reports, new release and other information can be obtained on SEDAR at www.sedar.com.